Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer
- 1 June 2004
- journal article
- case report
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 9 (3) , 206-209
- https://doi.org/10.1007/s10147-004-0394-4
Abstract
This report describes a patient with small-cell lung cancer who was infected with both Mycobacterium tuberculosis and non-tuberculous mycobacterium. He received irinotecan plus cisplatin, with and without rifampin. Rifampin slightly reduced the conversion of irinotecan to 7-ethyl-10-hydroxycamptothecin (SN-38), as determined by pharmacokinetic analysis. Rifampin may influence the metabolism and toxicity of irinotecan to some extent. However, there are possibilities to control M. tuberculosis and Mycobacterium avium complex infections in patients with small-cell lung cancer by using rifampin in combination with irinotecan plus cisplatin.Keywords
This publication has 0 references indexed in Scilit: